Accordingly, the inhibition of NLRP3 reduces the cytokine storm and lung injury induced by SARS-CoV-2 infection [58], suggesting that the development of NLRP3 inhibitors for clinical use in COVID-19 may prove valuable. The gene discussed is NLRP3; the disease is COVID-19.